Vor Biopharma Inc.

Stage 3 · Topping · week 2

As of Oct 22, 2026, Vor Biopharma is in Stage 3, the topping phase, now in week 2 (since Oct 15, 2026). It closed at $18.94, 32.7% below its 52-week high and above its 200-day average, which is rising.

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. More about the company

$18.94

-0.32% today

$1.1B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is VOR early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 19w

S4 40w

S1 18w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 19w → S1 10w → S4 40w → S1 6w → S2 7w → S3 4w → S4 11w → S1 2w → S2 10w → S3 9w → S4 10w → S1 18w → S4 3w → S1 2w → S2 12w → S3 1w current

Total tracked: 165 weeks across 16 stage runs.

VOR among Biotechnology290th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…290	VORVor Biopharma Inc.	Stage 3 · wk 2	32	−2.2%

vs 52W High

-32.7%

$6.86 lo$28.13 hi

32.7% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 2

1w13w26w

Week 2, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

10.4%

200 DMA: $17.16 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.72x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-2.2%

-1.7%

+29.5%

YTD

+62.7%

-31.8%

Scan Membership

Breakout Watch

Latest: 2025-01-30

2 appearances in last 60 days. First seen: 2022-12-29.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 2 · Vol 0.72x

2026-10-21S3

Wk 1 · Vol 0.72x

2026-10-20S3

Wk 1 · Vol 0.80x

2026-10-19S3

Wk 1 · Vol 0.73x

2026-10-16S3

Wk 1 · Vol 0.73x

2026-10-15S32→3

Wk 1 · Vol 0.70x

2026-10-14S2

Wk 12 · Vol 0.93x

2026-10-13S2

Wk 12 · Vol 0.95x

2026-10-12S2

Wk 12 · Vol 0.87x

2026-10-09S2

Wk 12 · Vol 1.11x

2026-10-08S2

Wk 12 · Vol 1.43x

2026-10-07S2

Wk 11 · Vol 0.57x

Moving averages & range

50 DMA

$21.19

200 DMA

$17.16

52W High

$28.13

52W Low

$6.86

5D Low

$18.03

Resistance levels (recent highs)

20d High

$19.90

60d High

$25.10

120d High

$25.10

250d High

$28.13

Next resistance

+5.1%

to 20d High

P/E (TTM)

0.1

Forward -5.2

Dividend Yield

0.00%

P/B -5.2

Vor Biopharma: quick answers

What stage is Vor Biopharma in?

As of Oct 22, 2026, Vor Biopharma (VOR) is in Stage 3, the topping phase. It entered Stage 3 on Oct 15, 2026 and is in week 2. What the four stages mean

Is Vor Biopharma in an uptrend?

Its uptrend has stalled. Vor Biopharma is in Stage 3, the topping phase that follows an advance. It trades 10.4% above its 200-day average, which is rising.

How far is Vor Biopharma from its 52-week high?

Vor Biopharma closed at $18.94 on Oct 22, 2026, 32.7% below its 52-week high of $28.13. Its 52-week low is $6.86.

How has Vor Biopharma performed over the past year?

As of Oct 22, 2026, Vor Biopharma is down 31.8% over the past year and up 62.7% so far in 2026.

Which sector and industry is Vor Biopharma in?

Vor Biopharma is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.